YMAB Stock Overview
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Y-mAbs Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.00 |
| 52 Week High | US$20.90 |
| 52 Week Low | US$4.60 |
| Beta | 0.76 |
| 1 Month Change | 0.74% |
| 3 Month Change | 59.91% |
| 1 Year Change | 157.73% |
| 3 Year Change | -44.53% |
| 5 Year Change | -36.25% |
| Change since IPO | -37.50% |
Recent News & Updates
Recent updates
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
Mar 14
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry
Feb 17Y-mAbs Therapeutics: A Monoclonal Antibody Play
Jan 14We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate
Nov 13We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth
Jul 16Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts
May 13Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%
Apr 17Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely
Mar 22We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully
Dec 13Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically
Aug 13Y-mAbs gets FDA nod to begin phase 1 study of GD2-SADA for certain cancers
Jul 12Y-mAbs Therapeutics: Steady, Small Steps Targeting Rare Cancers
May 30Is Y-mAbs Therapeutics (NASDAQ:YMAB) In A Good Position To Invest In Growth?
May 12Y-mAbs Therapeutics (NASDAQ:YMAB) Is In A Good Position To Deliver On Growth Plans
Dec 09Shareholder Returns
| YMAB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.5% | -4.7% | -3.7% |
| 1Y | 157.7% | -2.7% | 20.2% |
Return vs Industry: YMAB exceeded the US Biotechs industry which returned -2% over the past year.
Return vs Market: YMAB exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| YMAB volatility | |
|---|---|
| YMAB Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: YMAB's share price has been volatile over the past 3 months.
Volatility Over Time: YMAB's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 100 | Mike Rossi | www.ymabs.com |
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform.
Y-mAbs Therapeutics, Inc. Fundamentals Summary
| YMAB fundamental statistics | |
|---|---|
| Market cap | US$656.66m |
| Earnings (TTM) | -US$21.43m |
| Revenue (TTM) | US$84.82m |
7.7x
P/S Ratio-30.6x
P/E RatioIs YMAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| YMAB income statement (TTM) | |
|---|---|
| Revenue | US$84.82m |
| Cost of Revenue | US$11.42m |
| Gross Profit | US$73.40m |
| Other Expenses | US$94.83m |
| Earnings | -US$21.43m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.49 |
| Gross Margin | 86.54% |
| Net Profit Margin | -25.26% |
| Debt/Equity Ratio | 0% |
How did YMAB perform over the long term?
See historical performance and comparison